Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ)

• Company Description    Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO. Number of Employees: 497

• Price / Volume Information    Yesterday's Closing Price: $29.79 Daily Weekly Monthly 20 Day Moving Average: 1,425,769 shares Shares Outstanding: 92.24 (millions) Market Capitalization: $2,747.88 (millions) Beta: 0.81 52 Week High: $42.13 52 Week Low: $12.91 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.18% -3.34% 12 Week -14.89% -14.99% Year To Date -22.04% -22.41%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3611 VALLEY CENTRE DR SUITE 300 - SAN DIEGO,CA 92130 USA ph: 888-969-7879 fax: 302-645-1280 ir@travere.com http://www.travere.com

• General Corporate Information    Officers Eric Dube - Chief Executive Officer Gary Lyons - Chairman Christopher Cline - Chief Financial Officer Sandra Calvin - Senior Vice President and Chief Accounting Officer Roy D. Baynes - Director Peer Information Travere Therapeutics, Inc. (CORR.) Travere Therapeutics, Inc. (RSPI) Travere Therapeutics, Inc. (CGXP) Travere Therapeutics, Inc. (BGEN) Travere Therapeutics, Inc. (GTBP) Travere Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 89422G107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/25 Next Expected EPS Date: 05/07/26 Share - Related Items Shares Outstanding: 92.24 Most Recent Split Date: (:1) Beta: 0.81 Market Capitalization: $2,747.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/07/26

• Fundamental Ratios P/E Current FY Estimate: 1,489.50 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 23.21 Price/Cash Flow: 82.26 Price / Sales: 5.60 EPS Growth vs. Year Ago Period: 104.11% vs. Previous Quarter: -89.29% Sales Growth vs. Year Ago Period: 73.41% vs. Previous Quarter: -21.33% ROE 12/31/25 - -40.24 09/30/25 - -178.68 06/30/25 - -717.68 ROA 12/31/25 - -4.55 09/30/25 - -15.83 06/30/25 - -30.69 Current Ratio 12/31/25 - 2.74 09/30/25 - 2.75 06/30/25 - 2.00 Quick Ratio 12/31/25 - 2.70 09/30/25 - 2.71 06/30/25 - 1.98 Operating Margin 12/31/25 - -5.21 09/30/25 - -20.32 06/30/25 - -50.62 Net Margin 12/31/25 - -5.21 09/30/25 - -20.32 06/30/25 - -50.64 Pre-Tax Margin 12/31/25 - -10.04 09/30/25 - -20.32 06/30/25 - -50.65 Book Value 12/31/25 - 1.28 09/30/25 - 0.82 06/30/25 - 0.37 Inventory Turnover 12/31/25 - 2.13 09/30/25 - 2.09 06/30/25 - 2.02 Debt-to-Equity 12/31/25 - 2.71 09/30/25 - 4.23 06/30/25 - 9.50 Debt-to-Capital 12/31/25 - 73.08 09/30/25 - 80.89 06/30/25 - 90.47

Powered by Zacks Investment Research ©